MITO News and Press, Stealth BioTherapeutics Corp. From 04/11/22

Stealth BioTherapeutics (NASDAQ:MITO) enters agreement with a single healthcare-focused institutional investor to purchase in a registered direct offering 5,583,028 ADS, representing ~67M ordinary shares. Purchase price is $0.6269 per ADS for gross proceeds of ~$3.5M. Each ADS represents...

Stealth BioTherapeutics Announces $8.5 Million in Equity Financings PR Newswire BOSTON , April 11, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) (the "Company"), a clinical-stage biotechnology company focused on the discovery, developme...

Stealth BioTherapeutics Announces New SBT-272 Data and Trial Initiation PR Newswire BOSTON , March 30, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and comm...

Stealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for the Treatment of Friedreich's Ataxia PR Newswire Phase 2a clinical trial in Friedreich's ataxia has been initiated and is currently recruiting patients BOSTON , Mar...

Stealth BioTherapeutics Announces New Data on Complement Gene Expression and Cell Survival in Dry AMD to be Presented at ARVO (2022) PR Newswire BOSTON , March 24, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechn...

The U.S. Food and Drug Administration granted orphan drug designation to Stealth BioTherapeutics' (NASDAQ:MITO) elamipretide to treat Friedreich’s ataxia (FRDA). FRDA is a rare genetic, neurodegenerative movement disorder, whose symptoms may include frequent falling, difficulty in...

Stealth BioTherapeutics to Host Virtual Event on the Potential of Elamipretide in Treatment of Geographic Atrophy in Dry Age-Related Macular Degeneration PR Newswire BOSTON , March 17, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a cli...

Stealth BioTherapeutics Showcases New Duchenne Muscular Dystrophy Nonclinical Data at the 2022 Muscular Dystrophy Association and Clinical and Scientific Conference PR Newswire BOSTON , March 16, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a ...

NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the March 10 th Life Sciences Investor Forum are now available for on-demand viewing. REGISTER OR LOGIN NOW ...

Stealth BioTherapeutics to Present at Upcoming March Investor Conferences PR Newswire BOSTON , March 9, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and comm...